In most solid tumors, high tumor-infiltrating CD8+ T cells (immune infiltrated) predict good clinical outcomes treated with PD-1 blockade, while immune exclusion or immune desert is associated with resistance to these therapies (38–40). Here, CD8A is linked to neoplasm.